A nurse is caring for a client who is prescribed tetracycline 5 grams daily PO in divided doses every 8 hr. Available is tetracycline 500 mg capsules. How many capsules should the nurse administer per dose? (Round the answer to the nearest tenth. Use a leading zero if it applies. Do not use a trailing zero.)

A) Increase in the client's liver panel:
Fluconazole (Diflucan) is an antifungal medication that is metabolized in the liver, and one of the potential side effects of this drug is liver toxicity. This can manifest as an increase in liver enzymes (such as AST, ALT, or alkaline phosphatase) seen in the liver panel. It is important for the nurse to monitor the client’s liver function, especially if the patient has pre-existing liver conditions. If there are signs of liver toxicity, such as jaundice, abdominal pain, or elevated liver enzymes, the healthcare provider should be notified and the medication may need to be adjusted or discontinued.

B) Increase in the client's creatinine clearance:
Fluconazole is primarily eliminated through the kidneys, but it does not typically cause an increase in creatinine clearance. In fact, in patients with renal impairment, fluconazole can lead to an increase in serum creatinine levels due to reduced renal clearance of the drug. Therefore, a decrease (rather than an increase) in creatinine clearance is a more common concern, and renal function should be monitored during treatment.

C) Change of color to the client's secretions:
Fluconazole is not known to cause a change in the color of secretions (such as urine, saliva, or sweat). This side effect is more commonly associated with certain medications like rifampin (which can turn urine or sweat orange). However, fluconazole’s side effects are generally related to liver and renal function, as well as gastrointestinal disturbances, not to changes in secretions.

D) Red Man syndrome:
Red Man syndrome is a reaction typically associated with vancomycin, an antibiotic used for Gram-positive infections, especially when administered too rapidly via IV. It is characterized by flushing, rash, and hypotension, and is not a side effect of fluconazole. Fluconazole does not cause this type of infusion-related reaction, so this is not a concern with fluconazole therapy.

i) Neurotoxicity: Neomycin, an aminoglycoside antibiotic, can lead to neurotoxicity, manifesting as muscle weakness or respiratory paralysis due to its effects on neuromuscular transmission. This risk is especially significant in vulnerable populations like infants or clients with impaired renal function.

ii) Nephrotoxicity: Neomycin is known for its potential to cause kidney damage due to its accumulation in renal tubular cells, leading to acute tubular necrosis. Monitoring renal function is critical when administering this medication, particularly in young children who are more susceptible to such effects.

Incorrect:

Hepatotoxicity: Neomycin is not associated with liver toxicity, as it primarily affects the kidneys and nervous system.

Cardiotoxicity: This is not a recognized adverse effect of neomycin.

Dermatotoxicity: While aminoglycosides may cause mild skin irritation, serious dermatotoxicity is not typical for neomycin.

Ototoxicity: Though highly relevant to other aminoglycosides, ototoxicity is less pronounced with neomycin because it is minimally absorbed systemically when used topically or orally.

Hemotoxicity: Neomycin is not known to directly affect blood components.